Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mayne Pharma Group Limited announced the cessation of 17,656 performance rights due to unmet conditions, effective May 5, 2025. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting on the company’s operational adjustments and strategic focus.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceuticals. The company is known for its diverse range of oral and injectable products, catering to various therapeutic areas.
Average Trading Volume: 791,046
Technical Sentiment Signal: Hold
Current Market Cap: A$568.7M
Learn more about MYX stock on TipRanks’ Stock Analysis page.